Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Shares Issued: 2015-2024

Historic Preferred Shares Issued for Spyre Therapeutics (SYRE) over the last 2 years, with Sep 2024 value amounting to -$220,000.

  • Spyre Therapeutics' Preferred Shares Issued rose 98.26% to -$220,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $156.2 million, marking a year-over-year decrease of 20.85%. This contributed to the annual value of $197.4 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Spyre Therapeutics reported Preferred Shares Issued of -$220,000 as of Q3 2024, which was down 62.96% from -$135,000 recorded in Q2 2024.
  • In the past 5 years, Spyre Therapeutics' Preferred Shares Issued registered a high of $210.0 million during Q2 2023, and its lowest value of -$12.6 million during Q3 2023.
  • Over the past 2 years, Spyre Therapeutics' median Preferred Shares Issued value was -$135,000 (recorded in 2024), while the average stood at $73.2 million.
  • The largest annual percentage gain for Spyre Therapeutics' Preferred Shares Issued in the last 5 years was 98.26% (2024), contrasted with its biggest fall of 100.06% (2024).
  • Quarterly analysis of 2 years shows Spyre Therapeutics' Preferred Shares Issued stood at -$12.6 million in 2023, then spiked by 98.26% to -$220,000 in 2024.
  • Its last three reported values are -$220,000 in Q3 2024, -$135,000 for Q2 2024, and $169.2 million during Q1 2024.